CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Performance Share Units 10b5-1 | −20,000 | 0 | ||
| 2026-01-09 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Share Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-01-09 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Restricted Share Units | +20,000 | 20,000 | ||
| 2026-01-09 | Cline Darren S Chief Commercial Officer | Grant or award · Share Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-01-09 | Cline Darren S Chief Commercial Officer | Grant or award · Restricted Share Units | +20,000 | 20,000 | ||
| 2026-01-09 | DiFabio Andrea Chief Legal Officer | Grant or award · Share Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-01-09 | DiFabio Andrea Chief Legal Officer | Grant or award · Restricted Share Units | +15,000 | 15,000 | ||
| 2026-01-09 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Share Option (Right to Buy) | +350,000 | 350,000 | ||
| 2026-01-09 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Restricted Share Units | +65,000 | 65,000 | ||
| 2026-01-02 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +40,000 | $7.49 | $300K | 46,000 |
| 2026-01-02 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −37,938 | $44.40 | $1.7M | 8,062 |
| 2026-01-02 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −2,062 | $44.93 | $93K | 6,000 |
| 2026-01-02 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,000 | 0 | ||
| 2025-12-08 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −8,820 | $45.59 | $402K | 8,010 |
| 2025-12-08 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −2,010 | $46.32 | $93K | 6,000 |
| 2025-12-05 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −14,375 | $45.03 | $647K | 16,830 |
| 2025-11-28 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −97 | $45.01 | $4K | 31,205 |
| 2025-10-15 | Kelly Thomas Patrick Chief Financial Officer | Grant or award · Share Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-10-15 | Kelly Thomas Patrick Chief Financial Officer | Grant or award · Restricted Share Units | +30,000 | 30,000 | ||
| 2025-10-01 | MORTIMER IAN PRESIDENT, CEO & INTERIM CFO | Option exercise 10b5-1 | +25,000 | $7.69 | $192K | 56,302 |
Page 5 of 16 · 308 trades